It has been shown that patient accessibility to antibody-drug conjugates (ADCs) introduced in Korea has been significantly reduced due to high non-reimbursed drug prices. The price of non-reimbursed Trodelvy, which was approved in Korea last May, is about 1.6 million won per vial. Converted into one cycle (21 days, 2 administrations), the cost is approximately 9.3 million won, which is close to 10 million won. Enhertu’s non-reimbursed drug price is also high. The non-reimbursed price of Enhertu, which requires three vials per cycle for an average patient is about 7 million won. If you participate in the Patient Assistant Program (PAP) run by the company, the price drops to the high 5 million won range, but it is still a